"Tasty&Healthy" Dietary Approach for Crohn's Disease
Crohn Disease
About this trial
This is an interventional treatment trial for Crohn Disease
Eligibility Criteria
Inclusion Criteria:
ACTIVE-RCT-I
- Children and young adults aged 6-24 years with established diagnosis of CD by European crohn's and colitis organisation (ECCO) /The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria.
- <1 years of disease duration since the time of CD diagnosis.
- Willingness to provide stool samples during the visits, at baseline, week 4 and week 8.
- Mild- moderate disease activity (wPCDAI 20-57.5 or CDAI 200-45) or milder disease (wPCDAI 12.5-57.5 or CDAI 150-450) that according to the physician's discretion warrants an immediate change in treatment (and thus cannot be included in the MH-RCT-II that has a non-treatment arm).
- Currently receiving no drug treatment or on maintenance treatment with immunomodulators (at stable dose for at least 16 weeks) or 5-aminosalicylic acid (5ASA)/sulfasalazine (at stable dose for at least 8 weeks). No current or prior treatment with biologics is allowed (i.e. biologic-naïve).
MH-RCT-II
- Children and young adults aged 6-40 years with established diagnosis of CD by ECCO/ESPGHAN criteria.
- <1 years of disease duration since the time of CD diagnosis, or <3 years of disease duration since the time of CD diagnosis for patients without evidence of significant bowel wall thickening (≤4 mm) without any damage as much as known.
- Willingness to provide stool samples during the visits, at baseline, week 4 and week 8.
- MINI ≥8 points.
- Clinical remission or at most minimal symptoms (wPCDAI<20/ CDAI<200) that according to the physician's discretion do not warrant immediate medical treatment.
- Receiving no treatment or on maintenance treatment with immunomodulators and/or first biologic (both at stable dose and interval for at least 16 weeks), and/or 5ASA/sulfasalazine (at stable dose for at least 8 weeks). Second biologic is not allowed.
Exclusion Criteria:
- Fibrostenotic or penetrating phenotype.
- Fistulizing perianal disease which is not in complete remission.
- "Ulcerative colitis (UC)-like" isolated Crohn's colitis.
- Prior failure of exclusive enteral nutrition or any other dietary intervention, for any reason.
- The use of steroids or budesonide in the recent month, or antibiotics prescribed to treat the CD in the previous two weeks.
- Any formula feed during the last month.
- Prior intestinal resection.
- Pregnancy.
- Celiac disease.
- For ACTIVE-RCT-I: any prior or concurrent biologic therapy; for MH-RCT-II: any prior or concurrent biologic therapy other than one first biologic
Sites / Locations
- Shaare Zedek Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
No Intervention
ACTIVE-RCT-I Tasty&Healthy intervention group
ACTIVE-RCT-I Control group
MH-RCT-II Tasty&Healthy intervention group
MH-RCT-II Control group
Patients with mild-moderately symptomatic disease, will follow the Tasty&Healthy dietary approach.
Patients with mild-moderately symptomatic disease, will receive EEN with Modulen formula only.
Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will follow the Tasty&Healthy dietary approach.
Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will continue their habitual diet.